Market Place
Sourcing Support
IO Biotech Publishes Data on IO112 Immune-Modulatory Cancer Vaccine
04 Feb 2025 //
GLOBENEWSWIRE
IO Biotech Completes Ph 2 Enrollment For IO102-IO103 In Melanoma
09 Jan 2025 //
GLOBENEWSWIRE
IO Biotech Secures €57.5 Million Debt Financing from EIB
20 Dec 2024 //
GLOBENEWSWIRE
IO Biotech Reports Q3 2024 Financial Results & Business Highlight
12 Nov 2024 //
GLOBENEWSWIRE
IO Biotech Announces Participation in Upcoming Investor Conferences
11 Nov 2024 //
GLOBENEWSWIRE
IO Biotech Reports Promising Results of IO102-IO103 in Lung Cancer
07 Nov 2024 //
GLOBENEWSWIRE
IO Biotech Announces Two Posters At SITC Annual Meeting
04 Oct 2024 //
GLOBENEWSWIRE
IO Biotech Announces Positive Phase 2 Results In Head And Neck Cancer
14 Sep 2024 //
GLOBENEWSWIRE
IO Biotech Updates On Pivotal Phase 3 Trial Of IO102-IO103 With Keytruda
30 Aug 2024 //
GLOBENEWSWIRE
IO Biotech Announces Participation in Upcoming Investor Conferences
26 Aug 2024 //
GLOBENEWSWIRE
IO Biotech Reports Q2 2024 Results And Business Highlights
13 Aug 2024 //
GLOBENEWSWIRE
IO Biotech To Present Head And Neck Data At ESMO 2024
25 Jul 2024 //
GLOBENEWSWIRE
IO Biotech to Present at Jefferies Global Healthcare Conference
23 May 2024 //
GLOBENEWSWIRE
IO Biotech Reports Q1 2024 Results, Business Highlights
14 May 2024 //
GLOBENEWSWIRE
IO Biotech Abstract Accepted for ASCO 2024 Presentation
24 Apr 2024 //
GLOBENEWSWIRE
IO Biotech Expands Leadership For Commercialization
15 Apr 2024 //
GLOBENEWSWIRE
IO Biotech Presents Dual-action Cancer Vaccine Data at AACR
09 Apr 2024 //
GLOBENEWSWIRE
IO Biotech Appoints Faiçal Miyara, Ph.D., as Chief Business Officer
05 Apr 2024 //
GLOBENEWSWIRE
IO Biotech Announces Acceptance of Abstract to be Presented
06 Mar 2024 //
GLOBENEWSWIRE
IO Biotech Announces 2023 Fourth-Quarter and Year-End Results
05 Mar 2024 //
GLOBENEWSWIRE
IO Biotech to Present at 44th Annual Cowen Health Care Conference
26 Feb 2024 //
GLOBENEWSWIRE
IO Biotech Announces First Patient Dosed in Phase 2 Solid Tumor Basket Trial
21 Dec 2023 //
GLOBENEWSWIRE
IO Biotech Appoints Helen Collins, MD, to its Board of Directors
13 Nov 2023 //
GLOBENEWSWIRE
IO Biotech Announces 2023 Third Quarter Results
13 Nov 2023 //
GLOBENEWSWIRE
IO Bio Completes Enrollment of 380 Patients in Pivotal Phase 3 Trial in Melanoma
10 Nov 2023 //
GLOBENEWSWIRE
IO Biotech Announces Participation in Upcoming Investor Conferences
08 Nov 2023 //
GLOBENEWSWIRE
IO Biotech Presents Three Posters at SITC 38th Annual Meeting
01 Nov 2023 //
GLOBENEWSWIRE
Encouraging Preliminary Data from a Phase 2 Trial Evaluating IO102-IO103
23 Oct 2023 //
GLOBENEWSWIRE
IO Biotech Announces Three Poster Presentations at the SITC
03 Oct 2023 //
GLOBENEWSWIRE
IO Biotech Announces Data Related to IO102-IO103 Cancer Vaccine Presented
12 Sep 2023 //
GLOBENEWSWIRE
IO Biotech Announces Participation in Upcoming Investor Conferences
06 Sep 2023 //
GLOBENEWSWIRE
IO Biotech Appoints Heidi Hunter to its Board of Directors
11 Aug 2023 //
GLOBENEWSWIRE
IO Biotech Announces 2023 Second Quarter Results
11 Aug 2023 //
GLOBENEWSWIRE
IO Biotech Announces Abstract Accepted for Presentation at ESMO Congress 2023
08 Aug 2023 //
GLOBENEWSWIRE
IO Biotech, Inc. Announces $75 Million Private Placement Financing
07 Aug 2023 //
GLOBENEWSWIRE
IO Biotech Announces First Patient Dosed in Investigator-Initiated Phase 1 Trial
28 Jul 2023 //
GLOBENEWSWIRE
IO Biotech Announces Abstract Accepted for Mini Oral Presentation at IASLC
25 Jul 2023 //
GLOBENEWSWIRE
IO Biotech Appoints Qasim Ahmad, MD, as Chief Medical Officer
18 Jul 2023 //
GLOBENEWSWIRE
IO Biotech Announces Achievement of Phase 3 Trial Recruitment Milestone
14 Jun 2023 //
GLOBENEWSWIRE
IO Biotech Appoints Christine Richter MBA, as Senior Vice President
01 Jun 2023 //
GLOBENEWSWIRE
IO Biotech to Present at the Jefferies Healthcare Conference
30 May 2023 //
GLOBENEWSWIRE
IO Biotech Announces 2022 Fourth-Quarter and Year-End Results
14 Mar 2023 //
GLOBENEWSWIRE
IO Biotech to Participate in March 2023 Investor Conferences
22 Feb 2023 //
GLOBENEWSWIRE
IO Biotech Announces Appointment of Devin Smith as General Counsel
23 Jan 2023 //
GLOBENEWSWIRE
IO Biotech Provides Business Update
09 Jan 2023 //
GLOBENEWSWIRE
IO Biotech Announces an Invited Oral Presentation and Two Poster Presentations
09 Nov 2022 //
GLOBENEWSWIRE
IO Biotech Announces Clinical Collaboration with Merck to Evaluate Neoadjuvant
03 Nov 2022 //
GLOBENEWSWIRE
IO Biotech to Participate in the Jefferies London Healthcare Conference
31 Oct 2022 //
GLOBENEWSWIRE
IO Biotech Announces Appointment of New Chief Financial Officer
13 Oct 2022 //
GLOBENEWSWIRE
IO Biotech Announces Invited Oral Presentation and Two Poster Presentations
05 Oct 2022 //
GLOBENEWSWIRE
IO Biotech Announces Second Quarter Results for 2022
11 Aug 2022 //
GLOBENEWSWIRE
IO Biotech to Participate in the 2022 BIO International Convention
06 Jun 2022 //
GLOBENEWSWIRE
IO Biotech Announces Two Presentations at the ASCO 2022
26 May 2022 //
GLOBENEWSWIRE
IO Biotech to Participate in the Jefferies Healthcare Conference
23 May 2022 //
GLOBENEWSWIRE
IO Biotech Initiates PIII Combination Trial of IO102-IO103 and KEYTRUDA
18 May 2022 //
GLOBENEWSWIRE
IO Biotech Announces First Quarter Results for 2022
16 May 2022 //
GLOBENEWSWIRE
IO Biotech Initiates PII Trial of IO102-IO103+ KEYTRUDA as 1L Treatment
12 Apr 2022 //
GLOBENEWSWIRE
IO Biotech Presents New Data from MM1636 Phase 1/2 Trial at AACR
08 Apr 2022 //
GLOBENEWSWIRE
IO Biotech Announces Year-End Results for 2021
31 Mar 2022 //
GLOBENEWSWIRE
IO Biotech says Acceptance of Abstract to be Presented at AACR
08 Mar 2022 //
GLOBENEWSWIRE
